Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes.

By I. Lossos, D. Czerwinski, Ash A. Alizadeh, M. Wechser, Robert Tibshirani, David Botstein, R. Levy. New England Journal of Medicine, 2004

947 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

MicroRNA signature predicts survival and relapse in lung cancer. (2008, methodology): “In fact, the results of predictor power generated from microRNA or mRNA signatures had been reported in the literature (Beer et al., 2002; Bloomston et al., 2007; Calin et al., 2005; Chen et al., 2007; Endoh et al., 2004; Lossos et al., 2004; Potti et al., 2006; Yanaihara et al., 2006).”
Google Goes Cancer: Improving Outcome Prediction for Cancer Patients by Network-Based Ranking of Marker Genes (2012, background): “lung cancer [6–8], lymphomas [9–13], leukemia [14,15], and”
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. (2014, methodology): “In patients with diffuse large B-cell lymphoma (DLBCL), levels of serum IL-6 have been used as a prognostic indicator of clinical response and overall survival (Lossos et al., 2004).”
Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. (2010, methodology): “We assigned each patient a risk score according to a linear combination of the expression level of the miRNA, weighted by the regression coefficient from the training samples.(2,11,17) The risk score was calculated as follows: risk-score (0.”